Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

医学 聚乙二醇干扰素 乙型肝炎表面抗原 内科学 HBeAg 胃肠病学 养生 乙型肝炎 乙型肝炎病毒 α-干扰素 α-干扰素 免疫学 干扰素 慢性肝炎 病毒 利巴韦林
作者
Marc Bourlière,Pascaline Rabiéga,Nathalie Ganne‐Carrié,Lawrence Serfaty,Patrick Marcellin,Yoann Barthe,Dominique Thabut,Dominique Guyader,Christophe Hézode,Magali Picon,Xavier Causse,Vincent Leroy,J.-P. Bronowicki,Patrizia Carrieri,Ghassan Riachi,Isabelle Rosa,P Attali,Jean‐Michel Molina,Yannick Bacq,Albert Tran,Jean Didier Grangè,Fabien Zoulim,Hélène Fontaine,Laurent Alric,Inga Bertucci,Magali Bouvier–Alias,Fabrice Carrat
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:2 (3): 177-188 被引量:90
标识
DOI:10.1016/s2468-1253(16)30189-3
摘要

Background Findings from uncontrolled studies suggest that addition of pegylated interferon in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos(t)ide analogues with undetectable plasma hepatitis B virus (HBV) DNA might increase HBs antigen (HBsAg) clearance. We aimed to assess this strategy. Methods In this randomised, controlled, open-label trial, we enrolled patients aged 18–75 years with HBeAg-negative chronic hepatitis B and documented negative HBV DNA while on stable nucleos(t)ide analogue regimens for at least 1 year from 30 hepatology tertiary care wards in France. Patients had to have an alanine aminotransferase concentration of less than or equal to five times the upper normal range, no hepatocellular carcinoma, and a serum α fetoprotein concentration of less than 50 ng/mL, normal dilated fundus oculi examination, and a negative pregnancy test in women. Patients with contraindications to pegylated interferon were not eligible. A centralised randomisation used computer-generated lists of random permuted blocks of four with stratification by HBsAg titres (< or ≥2·25 log10 IU/mL) to allocate patients (1:1) to receive a 48 week course of subcutaneous injections of 180 μg per week of pegylated interferon alfa-2a in addition to the nucleos(t)ide analogue regimen or to continue to receive nucleos(t)ide analogues only. The primary endpoint was HBsAg loss at week 96 by intention-to-treat analysis. This trial is closed and registered with ClinicalTrials.gov, number NCT01172392. Findings Between Jan 20, 2011, and July 18, 2012, we randomly allocated 185 patients (92 [50%] to pegylated interferon and nucleos(t)ide analogues and 93 [50%] to nucleos(t)ide analogues alone). We excluded two patients from the pegylated interferon plus nucleos(t)ide analogues group from analyses because of withdrawal of consent (one patient) or violation of inclusion criteria (one patient). At week 96, loss of HBsAg was reported in seven (7·8%) of 90 patients in the pegylated interferon plus nucleos(t)ide analogues group versus three (3·2%) of 93 in the nucleos(t)ide analogues-alone group (difference 4·6% [95% CI −2·6 to 12·5]; p=0·15). 85 (94%) of 90 patients started pegylated interferon, three (4%) of whom had a dose reduction and 17 (20%) had an early discontinuation of pegylated interferon (seven [41%] for serious adverse events). Grade 3 and 4 adverse events were more frequent in the pegylated interferon plus nucleos(t)ide analogues group (26 [29%] grade 3 adverse events; 19 [21%] grade 4 adverse events) than in the nucleos(t)ide analogues-alone group (three [3%] grade 3; six [6%] grade 4). Interpretation Addition of a 48 week course of pegylated interferon to nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B with undetectable HBV DNA for a least 1 year was poorly tolerated and did not result in a significant increase of HBsAg clearance. Funding Institut national de la santé et de la recherche médicale-Agence nationale de recherches sur le sida et les hépatites virales (France Recherche Nord&sud Sida-vih Hepatites).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yins完成签到,获得积分10
刚刚
xia发布了新的文献求助10
1秒前
1秒前
秦淮完成签到,获得积分20
2秒前
可爱的函函应助mof采纳,获得10
2秒前
yins发布了新的文献求助10
3秒前
慕青应助NOEYEDEER采纳,获得10
4秒前
Jasper应助喵了个酥采纳,获得10
4秒前
5秒前
小饼干完成签到,获得积分10
6秒前
体贴的映阳关注了科研通微信公众号
7秒前
小饼干发布了新的文献求助10
9秒前
10秒前
科研通AI2S应助proteinpurify采纳,获得10
10秒前
11秒前
俊逸的问薇完成签到 ,获得积分10
12秒前
NOEYEDEER发布了新的文献求助10
14秒前
mof完成签到,获得积分10
15秒前
evergarden完成签到 ,获得积分10
15秒前
variant完成签到,获得积分10
18秒前
ananan完成签到,获得积分10
18秒前
NOEYEDEER完成签到,获得积分20
20秒前
20秒前
大模型应助bvuiragybv采纳,获得10
20秒前
20秒前
21秒前
David发布了新的文献求助10
21秒前
情怀应助sandra采纳,获得10
21秒前
Lucas应助我今停杯一问之采纳,获得10
23秒前
23秒前
zm完成签到,获得积分10
25秒前
佐zzz发布了新的文献求助10
25秒前
26秒前
26秒前
瑾笙发布了新的文献求助10
27秒前
29秒前
搜集达人应助冷艳的寻冬采纳,获得10
30秒前
zhangscience发布了新的文献求助10
31秒前
32秒前
已知中的未知完成签到,获得积分10
33秒前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
宽禁带半导体紫外光电探测器 388
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
Case Research: The Case Writing Process 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3142067
求助须知:如何正确求助?哪些是违规求助? 2793006
关于积分的说明 7805015
捐赠科研通 2449359
什么是DOI,文献DOI怎么找? 1303185
科研通“疑难数据库(出版商)”最低求助积分说明 626807
版权声明 601291